Cingulate, Inc. ( (CING) ) has released its Q2 earnings. Here is a breakdown of the information Cingulate, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cingulate Inc. is a biopharmaceutical company based in Kansas City, specializing in developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) drug delivery platform, with a primary focus on treating ADHD and anxiety disorders.
In its latest earnings report, Cingulate Inc. announced the submission of a New Drug Application (NDA) to the FDA for its lead product, CTx-1301, a novel ADHD treatment. The company anticipates a decision from the FDA in the fourth quarter of 2025, with a potential approval date in mid-2026.
Key financial highlights from the second quarter of 2025 include a net loss of $4.8 million, primarily driven by increased research and development expenses related to the NDA submission for CTx-1301. The company’s cash reserves stood at $8.9 million, with a working capital of $3.5 million. Cingulate also entered a purchase agreement with Lincoln Park Capital, allowing for the sale of up to $25 million in common stock over three years.
Cingulate’s strategic focus remains on advancing CTx-1301 towards commercialization, with plans to raise additional capital to support these efforts. The company’s innovative PTR platform continues to be a cornerstone of its strategy, offering potential improvements over existing ADHD treatments.
Looking ahead, Cingulate’s management is optimistic about the future, with plans to prioritize pre-commercial activities for CTx-1301 and explore additional therapeutic areas where its PTR technology can be applied, pending FDA approval.